nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—prostate cancer—bone cancer	0.671	1	CtDrD
Bicalutamide—CYP3A4—bone cancer	0.246	1	CbGaD
Bicalutamide—Enzalutamide—CYP3A4—bone cancer	0.00117	1	CrCbGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—T—bone cancer	0.000428	0.0593	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptors—NR1I2—bone cancer	0.000309	0.0428	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—FEV—bone cancer	0.000295	0.0409	CbGpPWpGaD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000261	0.0362	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000244	0.0338	CbGpPWpGaD
Bicalutamide—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000241	0.0334	CbGpPWpGaD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00024	0.0333	CbGpPWpGaD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000238	0.033	CbGpPWpGaD
Bicalutamide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000228	0.0315	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000157	0.0218	CbGpPWpGaD
Bicalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000148	0.0205	CbGpPWpGaD
Bicalutamide—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000139	0.0192	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000129	0.0178	CbGpPWpGaD
Bicalutamide—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000126	0.0175	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—ZNF77—bone cancer	0.000125	0.0173	CbGpPWpGaD
Bicalutamide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000121	0.0168	CbGpPWpGaD
Bicalutamide—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000116	0.0161	CbGpPWpGaD
Bicalutamide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000115	0.0159	CbGpPWpGaD
Bicalutamide—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000114	0.00153	CcSEcCtD
Bicalutamide—Decreased appetite—Cisplatin—bone cancer	0.000114	0.00153	CcSEcCtD
Bicalutamide—Bronchitis—Epirubicin—bone cancer	0.000114	0.00153	CcSEcCtD
Bicalutamide—Pneumonia—Methotrexate—bone cancer	0.000113	0.00152	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000113	0.00152	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000112	0.0156	CbGpPWpGaD
Bicalutamide—Depression—Methotrexate—bone cancer	0.000112	0.00151	CcSEcCtD
Bicalutamide—Gastritis—Doxorubicin—bone cancer	0.000112	0.0015	CcSEcCtD
Bicalutamide—Pain—Cisplatin—bone cancer	0.000112	0.0015	CcSEcCtD
Bicalutamide—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000112	0.0015	CcSEcCtD
Bicalutamide—Muscular weakness—Doxorubicin—bone cancer	0.000112	0.0015	CcSEcCtD
Bicalutamide—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000111	0.0154	CbGpPWpGaD
Bicalutamide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000111	0.0153	CbGpPWpGaD
Bicalutamide—Neutropenia—Epirubicin—bone cancer	0.00011	0.00148	CcSEcCtD
Bicalutamide—Dysuria—Epirubicin—bone cancer	0.00011	0.00148	CcSEcCtD
Bicalutamide—Conjunctivitis—Methotrexate—bone cancer	0.000109	0.00147	CcSEcCtD
Bicalutamide—Dysphagia—Doxorubicin—bone cancer	0.000109	0.00147	CcSEcCtD
Bicalutamide—Influenza—Doxorubicin—bone cancer	0.000109	0.00147	CcSEcCtD
Bicalutamide—Asthma—Doxorubicin—bone cancer	0.000109	0.00147	CcSEcCtD
Bicalutamide—Pollakiuria—Epirubicin—bone cancer	0.000109	0.00147	CcSEcCtD
Bicalutamide—Eosinophilia—Doxorubicin—bone cancer	0.000108	0.00145	CcSEcCtD
Bicalutamide—Sweating—Methotrexate—bone cancer	0.000108	0.00145	CcSEcCtD
Bicalutamide—Feeling abnormal—Cisplatin—bone cancer	0.000108	0.00145	CcSEcCtD
Bicalutamide—Weight increased—Epirubicin—bone cancer	0.000107	0.00145	CcSEcCtD
Bicalutamide—Haematuria—Methotrexate—bone cancer	0.000107	0.00144	CcSEcCtD
Bicalutamide—Weight decreased—Epirubicin—bone cancer	0.000107	0.00144	CcSEcCtD
Bicalutamide—Hyperglycaemia—Epirubicin—bone cancer	0.000107	0.00143	CcSEcCtD
Bicalutamide—Angina pectoris—Doxorubicin—bone cancer	0.000106	0.00143	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Methotrexate—bone cancer	0.000106	0.00143	CcSEcCtD
Bicalutamide—Epistaxis—Methotrexate—bone cancer	0.000106	0.00143	CcSEcCtD
Bicalutamide—Pneumonia—Epirubicin—bone cancer	0.000106	0.00142	CcSEcCtD
Bicalutamide—Bronchitis—Doxorubicin—bone cancer	0.000105	0.00141	CcSEcCtD
Bicalutamide—Body temperature increased—Cisplatin—bone cancer	0.000103	0.00139	CcSEcCtD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000103	0.0143	CbGpPWpGaD
Bicalutamide—Neuropathy peripheral—Epirubicin—bone cancer	0.000103	0.00139	CcSEcCtD
Bicalutamide—Jaundice—Epirubicin—bone cancer	0.000103	0.00138	CcSEcCtD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000102	0.0142	CbGpPWpGaD
Bicalutamide—Urinary tract infection—Epirubicin—bone cancer	0.000102	0.00138	CcSEcCtD
Bicalutamide—Conjunctivitis—Epirubicin—bone cancer	0.000102	0.00138	CcSEcCtD
Bicalutamide—Neutropenia—Doxorubicin—bone cancer	0.000102	0.00137	CcSEcCtD
Bicalutamide—Dysuria—Doxorubicin—bone cancer	0.000102	0.00137	CcSEcCtD
Bicalutamide—Haemoglobin—Methotrexate—bone cancer	0.000102	0.00137	CcSEcCtD
Bicalutamide—Haemorrhage—Methotrexate—bone cancer	0.000101	0.00136	CcSEcCtD
Bicalutamide—Sweating—Epirubicin—bone cancer	0.000101	0.00136	CcSEcCtD
Bicalutamide—Pollakiuria—Doxorubicin—bone cancer	0.000101	0.00136	CcSEcCtD
Bicalutamide—Haematuria—Epirubicin—bone cancer	0.0001	0.00135	CcSEcCtD
Bicalutamide—Pharyngitis—Methotrexate—bone cancer	0.0001	0.00135	CcSEcCtD
Bicalutamide—Urinary tract disorder—Methotrexate—bone cancer	9.98e-05	0.00134	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Epirubicin—bone cancer	9.96e-05	0.00134	CcSEcCtD
Bicalutamide—Weight increased—Doxorubicin—bone cancer	9.95e-05	0.00134	CcSEcCtD
Bicalutamide—Epistaxis—Epirubicin—bone cancer	9.93e-05	0.00134	CcSEcCtD
Bicalutamide—Urethral disorder—Methotrexate—bone cancer	9.9e-05	0.00133	CcSEcCtD
Bicalutamide—Weight decreased—Doxorubicin—bone cancer	9.89e-05	0.00133	CcSEcCtD
Bicalutamide—Sinusitis—Epirubicin—bone cancer	9.88e-05	0.00133	CcSEcCtD
Bicalutamide—Hyperglycaemia—Doxorubicin—bone cancer	9.86e-05	0.00133	CcSEcCtD
Bicalutamide—Pneumonia—Doxorubicin—bone cancer	9.8e-05	0.00132	CcSEcCtD
Bicalutamide—Visual impairment—Methotrexate—bone cancer	9.74e-05	0.00131	CcSEcCtD
Bicalutamide—Hypersensitivity—Cisplatin—bone cancer	9.64e-05	0.0013	CcSEcCtD
Bicalutamide—Bradycardia—Epirubicin—bone cancer	9.62e-05	0.00129	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Doxorubicin—bone cancer	9.55e-05	0.00128	CcSEcCtD
Bicalutamide—Haemoglobin—Epirubicin—bone cancer	9.5e-05	0.00128	CcSEcCtD
Bicalutamide—Jaundice—Doxorubicin—bone cancer	9.5e-05	0.00128	CcSEcCtD
Bicalutamide—Rhinitis—Epirubicin—bone cancer	9.48e-05	0.00127	CcSEcCtD
Bicalutamide—Conjunctivitis—Doxorubicin—bone cancer	9.47e-05	0.00127	CcSEcCtD
Bicalutamide—Urinary tract infection—Doxorubicin—bone cancer	9.47e-05	0.00127	CcSEcCtD
Bicalutamide—Haemorrhage—Epirubicin—bone cancer	9.45e-05	0.00127	CcSEcCtD
Bicalutamide—Asthenia—Cisplatin—bone cancer	9.38e-05	0.00126	CcSEcCtD
Bicalutamide—Pharyngitis—Epirubicin—bone cancer	9.38e-05	0.00126	CcSEcCtD
Bicalutamide—Cardiac disorder—Methotrexate—bone cancer	9.38e-05	0.00126	CcSEcCtD
Bicalutamide—Sweating—Doxorubicin—bone cancer	9.34e-05	0.00126	CcSEcCtD
Bicalutamide—Urinary tract disorder—Epirubicin—bone cancer	9.34e-05	0.00126	CcSEcCtD
Bicalutamide—Oedema peripheral—Epirubicin—bone cancer	9.31e-05	0.00125	CcSEcCtD
Bicalutamide—Haematuria—Doxorubicin—bone cancer	9.29e-05	0.00125	CcSEcCtD
Bicalutamide—Urethral disorder—Epirubicin—bone cancer	9.27e-05	0.00125	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Doxorubicin—bone cancer	9.22e-05	0.00124	CcSEcCtD
Bicalutamide—Epistaxis—Doxorubicin—bone cancer	9.19e-05	0.00124	CcSEcCtD
Bicalutamide—Angiopathy—Methotrexate—bone cancer	9.17e-05	0.00123	CcSEcCtD
Bicalutamide—Sinusitis—Doxorubicin—bone cancer	9.14e-05	0.00123	CcSEcCtD
Bicalutamide—Immune system disorder—Methotrexate—bone cancer	9.12e-05	0.00123	CcSEcCtD
Bicalutamide—Visual impairment—Epirubicin—bone cancer	9.11e-05	0.00122	CcSEcCtD
Bicalutamide—Mediastinal disorder—Methotrexate—bone cancer	9.1e-05	0.00122	CcSEcCtD
Bicalutamide—Chills—Methotrexate—bone cancer	9.06e-05	0.00122	CcSEcCtD
Bicalutamide—Diarrhoea—Cisplatin—bone cancer	8.95e-05	0.0012	CcSEcCtD
Bicalutamide—Alopecia—Methotrexate—bone cancer	8.93e-05	0.0012	CcSEcCtD
Bicalutamide—Bradycardia—Doxorubicin—bone cancer	8.91e-05	0.0012	CcSEcCtD
Bicalutamide—Mental disorder—Methotrexate—bone cancer	8.85e-05	0.00119	CcSEcCtD
Bicalutamide—Malnutrition—Methotrexate—bone cancer	8.79e-05	0.00118	CcSEcCtD
Bicalutamide—Haemoglobin—Doxorubicin—bone cancer	8.79e-05	0.00118	CcSEcCtD
Bicalutamide—Cardiac disorder—Epirubicin—bone cancer	8.77e-05	0.00118	CcSEcCtD
Bicalutamide—Rhinitis—Doxorubicin—bone cancer	8.77e-05	0.00118	CcSEcCtD
Bicalutamide—Haemorrhage—Doxorubicin—bone cancer	8.75e-05	0.00118	CcSEcCtD
Bicalutamide—Pharyngitis—Doxorubicin—bone cancer	8.68e-05	0.00117	CcSEcCtD
Bicalutamide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	8.65e-05	0.012	CbGpPWpGaD
Bicalutamide—Urinary tract disorder—Doxorubicin—bone cancer	8.64e-05	0.00116	CcSEcCtD
Bicalutamide—Oedema peripheral—Doxorubicin—bone cancer	8.62e-05	0.00116	CcSEcCtD
Bicalutamide—Angiopathy—Epirubicin—bone cancer	8.58e-05	0.00115	CcSEcCtD
Bicalutamide—Urethral disorder—Doxorubicin—bone cancer	8.57e-05	0.00115	CcSEcCtD
Bicalutamide—Immune system disorder—Epirubicin—bone cancer	8.54e-05	0.00115	CcSEcCtD
Bicalutamide—Mediastinal disorder—Epirubicin—bone cancer	8.52e-05	0.00115	CcSEcCtD
Bicalutamide—Back pain—Methotrexate—bone cancer	8.51e-05	0.00114	CcSEcCtD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	8.48e-05	0.0118	CbGpPWpGaD
Bicalutamide—Chills—Epirubicin—bone cancer	8.48e-05	0.00114	CcSEcCtD
Bicalutamide—Arrhythmia—Epirubicin—bone cancer	8.45e-05	0.00114	CcSEcCtD
Bicalutamide—Visual impairment—Doxorubicin—bone cancer	8.43e-05	0.00113	CcSEcCtD
Bicalutamide—Alopecia—Epirubicin—bone cancer	8.35e-05	0.00112	CcSEcCtD
Bicalutamide—Vomiting—Cisplatin—bone cancer	8.32e-05	0.00112	CcSEcCtD
Bicalutamide—Mental disorder—Epirubicin—bone cancer	8.28e-05	0.00111	CcSEcCtD
Bicalutamide—Rash—Cisplatin—bone cancer	8.25e-05	0.00111	CcSEcCtD
Bicalutamide—Dermatitis—Cisplatin—bone cancer	8.24e-05	0.00111	CcSEcCtD
Bicalutamide—Malnutrition—Epirubicin—bone cancer	8.23e-05	0.00111	CcSEcCtD
Bicalutamide—AR—Notch-mediated HES/HEY network—RB1—bone cancer	8.21e-05	0.0114	CbGpPWpGaD
Bicalutamide—Anaemia—Methotrexate—bone cancer	8.13e-05	0.00109	CcSEcCtD
Bicalutamide—Cardiac disorder—Doxorubicin—bone cancer	8.12e-05	0.00109	CcSEcCtD
Bicalutamide—Flatulence—Epirubicin—bone cancer	8.11e-05	0.00109	CcSEcCtD
Bicalutamide—Tension—Epirubicin—bone cancer	8.08e-05	0.00109	CcSEcCtD
Bicalutamide—Nervousness—Epirubicin—bone cancer	7.99e-05	0.00107	CcSEcCtD
Bicalutamide—Back pain—Epirubicin—bone cancer	7.96e-05	0.00107	CcSEcCtD
Bicalutamide—Angiopathy—Doxorubicin—bone cancer	7.94e-05	0.00107	CcSEcCtD
Bicalutamide—Muscle spasms—Epirubicin—bone cancer	7.91e-05	0.00106	CcSEcCtD
Bicalutamide—Immune system disorder—Doxorubicin—bone cancer	7.9e-05	0.00106	CcSEcCtD
Bicalutamide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	7.89e-05	0.0109	CbGpPWpGaD
Bicalutamide—Mediastinal disorder—Doxorubicin—bone cancer	7.88e-05	0.00106	CcSEcCtD
Bicalutamide—Chills—Doxorubicin—bone cancer	7.85e-05	0.00106	CcSEcCtD
Bicalutamide—Arrhythmia—Doxorubicin—bone cancer	7.81e-05	0.00105	CcSEcCtD
Bicalutamide—Nausea—Cisplatin—bone cancer	7.77e-05	0.00104	CcSEcCtD
Bicalutamide—Alopecia—Doxorubicin—bone cancer	7.73e-05	0.00104	CcSEcCtD
Bicalutamide—Cough—Methotrexate—bone cancer	7.67e-05	0.00103	CcSEcCtD
Bicalutamide—Mental disorder—Doxorubicin—bone cancer	7.66e-05	0.00103	CcSEcCtD
Bicalutamide—Malnutrition—Doxorubicin—bone cancer	7.61e-05	0.00102	CcSEcCtD
Bicalutamide—Anaemia—Epirubicin—bone cancer	7.61e-05	0.00102	CcSEcCtD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	7.52e-05	0.0104	CbGpPWpGaD
Bicalutamide—Flatulence—Doxorubicin—bone cancer	7.5e-05	0.00101	CcSEcCtD
Bicalutamide—Myalgia—Methotrexate—bone cancer	7.49e-05	0.00101	CcSEcCtD
Bicalutamide—Chest pain—Methotrexate—bone cancer	7.49e-05	0.00101	CcSEcCtD
Bicalutamide—Tension—Doxorubicin—bone cancer	7.47e-05	0.001	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.44e-05	0.001	CcSEcCtD
Bicalutamide—Nervousness—Doxorubicin—bone cancer	7.4e-05	0.000994	CcSEcCtD
Bicalutamide—Syncope—Epirubicin—bone cancer	7.38e-05	0.000992	CcSEcCtD
Bicalutamide—Back pain—Doxorubicin—bone cancer	7.37e-05	0.00099	CcSEcCtD
Bicalutamide—Muscle spasms—Doxorubicin—bone cancer	7.32e-05	0.000984	CcSEcCtD
Bicalutamide—Confusional state—Methotrexate—bone cancer	7.24e-05	0.000973	CcSEcCtD
Bicalutamide—Loss of consciousness—Epirubicin—bone cancer	7.23e-05	0.000973	CcSEcCtD
Bicalutamide—Cough—Epirubicin—bone cancer	7.18e-05	0.000966	CcSEcCtD
Bicalutamide—Infection—Methotrexate—bone cancer	7.13e-05	0.000959	CcSEcCtD
Bicalutamide—Hypertension—Epirubicin—bone cancer	7.11e-05	0.000955	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	7.04e-05	0.00975	CbGpPWpGaD
Bicalutamide—Nervous system disorder—Methotrexate—bone cancer	7.04e-05	0.000946	CcSEcCtD
Bicalutamide—Anaemia—Doxorubicin—bone cancer	7.04e-05	0.000946	CcSEcCtD
Bicalutamide—Thrombocytopenia—Methotrexate—bone cancer	7.03e-05	0.000945	CcSEcCtD
Bicalutamide—Myalgia—Epirubicin—bone cancer	7.01e-05	0.000942	CcSEcCtD
Bicalutamide—Chest pain—Epirubicin—bone cancer	7.01e-05	0.000942	CcSEcCtD
Bicalutamide—Anxiety—Epirubicin—bone cancer	6.98e-05	0.000939	CcSEcCtD
Bicalutamide—Skin disorder—Methotrexate—bone cancer	6.97e-05	0.000937	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	6.96e-05	0.000936	CcSEcCtD
Bicalutamide—Hyperhidrosis—Methotrexate—bone cancer	6.94e-05	0.000933	CcSEcCtD
Bicalutamide—Dry mouth—Epirubicin—bone cancer	6.85e-05	0.000921	CcSEcCtD
Bicalutamide—Anorexia—Methotrexate—bone cancer	6.84e-05	0.00092	CcSEcCtD
Bicalutamide—Syncope—Doxorubicin—bone cancer	6.83e-05	0.000918	CcSEcCtD
Bicalutamide—Confusional state—Epirubicin—bone cancer	6.77e-05	0.000911	CcSEcCtD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	6.76e-05	0.00936	CbGpPWpGaD
Bicalutamide—Oedema—Epirubicin—bone cancer	6.72e-05	0.000903	CcSEcCtD
Bicalutamide—Loss of consciousness—Doxorubicin—bone cancer	6.69e-05	0.0009	CcSEcCtD
Bicalutamide—Infection—Epirubicin—bone cancer	6.67e-05	0.000897	CcSEcCtD
Bicalutamide—Cough—Doxorubicin—bone cancer	6.64e-05	0.000893	CcSEcCtD
Bicalutamide—Shock—Epirubicin—bone cancer	6.61e-05	0.000888	CcSEcCtD
Bicalutamide—Nervous system disorder—Epirubicin—bone cancer	6.59e-05	0.000886	CcSEcCtD
Bicalutamide—Thrombocytopenia—Epirubicin—bone cancer	6.58e-05	0.000884	CcSEcCtD
Bicalutamide—Hypertension—Doxorubicin—bone cancer	6.57e-05	0.000884	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Methotrexate—bone cancer	6.54e-05	0.000879	CcSEcCtD
Bicalutamide—Skin disorder—Epirubicin—bone cancer	6.52e-05	0.000877	CcSEcCtD
Bicalutamide—Hyperhidrosis—Epirubicin—bone cancer	6.49e-05	0.000873	CcSEcCtD
Bicalutamide—Insomnia—Methotrexate—bone cancer	6.49e-05	0.000873	CcSEcCtD
Bicalutamide—Chest pain—Doxorubicin—bone cancer	6.48e-05	0.000872	CcSEcCtD
Bicalutamide—Myalgia—Doxorubicin—bone cancer	6.48e-05	0.000872	CcSEcCtD
Bicalutamide—Anxiety—Doxorubicin—bone cancer	6.46e-05	0.000869	CcSEcCtD
Bicalutamide—Paraesthesia—Methotrexate—bone cancer	6.44e-05	0.000866	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	6.44e-05	0.000866	CcSEcCtD
Bicalutamide—AR—FOXA1 transcription factor network—JUN—bone cancer	6.42e-05	0.00889	CbGpPWpGaD
Bicalutamide—Anorexia—Epirubicin—bone cancer	6.4e-05	0.000861	CcSEcCtD
Bicalutamide—Dyspnoea—Methotrexate—bone cancer	6.4e-05	0.00086	CcSEcCtD
Bicalutamide—Somnolence—Methotrexate—bone cancer	6.38e-05	0.000858	CcSEcCtD
Bicalutamide—AR—Regulation of Androgen receptor activity—MDM2—bone cancer	6.36e-05	0.00881	CbGpPWpGaD
Bicalutamide—Dry mouth—Doxorubicin—bone cancer	6.34e-05	0.000852	CcSEcCtD
Bicalutamide—Dyspepsia—Methotrexate—bone cancer	6.32e-05	0.000849	CcSEcCtD
Bicalutamide—Confusional state—Doxorubicin—bone cancer	6.27e-05	0.000843	CcSEcCtD
Bicalutamide—Decreased appetite—Methotrexate—bone cancer	6.24e-05	0.000839	CcSEcCtD
Bicalutamide—Oedema—Doxorubicin—bone cancer	6.21e-05	0.000836	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Methotrexate—bone cancer	6.2e-05	0.000833	CcSEcCtD
Bicalutamide—Fatigue—Methotrexate—bone cancer	6.19e-05	0.000832	CcSEcCtD
Bicalutamide—Infection—Doxorubicin—bone cancer	6.17e-05	0.00083	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—ATF1—bone cancer	6.14e-05	0.00851	CbGpPWpGaD
Bicalutamide—Pain—Methotrexate—bone cancer	6.14e-05	0.000825	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Epirubicin—bone cancer	6.12e-05	0.000823	CcSEcCtD
Bicalutamide—Shock—Doxorubicin—bone cancer	6.11e-05	0.000822	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	6.11e-05	0.00847	CbGpPWpGaD
Bicalutamide—Nervous system disorder—Doxorubicin—bone cancer	6.09e-05	0.000819	CcSEcCtD
Bicalutamide—Thrombocytopenia—Doxorubicin—bone cancer	6.08e-05	0.000818	CcSEcCtD
Bicalutamide—Insomnia—Epirubicin—bone cancer	6.07e-05	0.000817	CcSEcCtD
Bicalutamide—Skin disorder—Doxorubicin—bone cancer	6.04e-05	0.000812	CcSEcCtD
Bicalutamide—Paraesthesia—Epirubicin—bone cancer	6.03e-05	0.000811	CcSEcCtD
Bicalutamide—Hyperhidrosis—Doxorubicin—bone cancer	6.01e-05	0.000808	CcSEcCtD
Bicalutamide—AR—Gene Expression—ZNF77—bone cancer	6e-05	0.00832	CbGpPWpGaD
Bicalutamide—Dyspnoea—Epirubicin—bone cancer	5.99e-05	0.000805	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.98e-05	0.00829	CbGpPWpGaD
Bicalutamide—Somnolence—Epirubicin—bone cancer	5.97e-05	0.000803	CcSEcCtD
Bicalutamide—Anorexia—Doxorubicin—bone cancer	5.92e-05	0.000796	CcSEcCtD
Bicalutamide—Feeling abnormal—Methotrexate—bone cancer	5.91e-05	0.000795	CcSEcCtD
Bicalutamide—Dyspepsia—Epirubicin—bone cancer	5.91e-05	0.000795	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	5.91e-05	0.00819	CbGpPWpGaD
Bicalutamide—Gastrointestinal pain—Methotrexate—bone cancer	5.87e-05	0.000789	CcSEcCtD
Bicalutamide—Decreased appetite—Epirubicin—bone cancer	5.84e-05	0.000785	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Epirubicin—bone cancer	5.8e-05	0.00078	CcSEcCtD
Bicalutamide—Fatigue—Epirubicin—bone cancer	5.79e-05	0.000779	CcSEcCtD
Bicalutamide—Pain—Epirubicin—bone cancer	5.74e-05	0.000772	CcSEcCtD
Bicalutamide—Constipation—Epirubicin—bone cancer	5.74e-05	0.000772	CcSEcCtD
Bicalutamide—Urticaria—Methotrexate—bone cancer	5.7e-05	0.000767	CcSEcCtD
Bicalutamide—Body temperature increased—Methotrexate—bone cancer	5.67e-05	0.000763	CcSEcCtD
Bicalutamide—Abdominal pain—Methotrexate—bone cancer	5.67e-05	0.000763	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Doxorubicin—bone cancer	5.66e-05	0.000761	CcSEcCtD
Bicalutamide—Insomnia—Doxorubicin—bone cancer	5.62e-05	0.000756	CcSEcCtD
Bicalutamide—Paraesthesia—Doxorubicin—bone cancer	5.58e-05	0.00075	CcSEcCtD
Bicalutamide—Dyspnoea—Doxorubicin—bone cancer	5.54e-05	0.000745	CcSEcCtD
Bicalutamide—Feeling abnormal—Epirubicin—bone cancer	5.53e-05	0.000744	CcSEcCtD
Bicalutamide—AR—Regulation of Androgen receptor activity—JUN—bone cancer	5.53e-05	0.00766	CbGpPWpGaD
Bicalutamide—Somnolence—Doxorubicin—bone cancer	5.52e-05	0.000743	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Epirubicin—bone cancer	5.49e-05	0.000738	CcSEcCtD
Bicalutamide—Dyspepsia—Doxorubicin—bone cancer	5.47e-05	0.000736	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	5.45e-05	0.00755	CbGpPWpGaD
Bicalutamide—Decreased appetite—Doxorubicin—bone cancer	5.4e-05	0.000726	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Doxorubicin—bone cancer	5.37e-05	0.000721	CcSEcCtD
Bicalutamide—Fatigue—Doxorubicin—bone cancer	5.36e-05	0.00072	CcSEcCtD
Bicalutamide—Urticaria—Epirubicin—bone cancer	5.34e-05	0.000717	CcSEcCtD
Bicalutamide—Pain—Doxorubicin—bone cancer	5.31e-05	0.000715	CcSEcCtD
Bicalutamide—Constipation—Doxorubicin—bone cancer	5.31e-05	0.000715	CcSEcCtD
Bicalutamide—Abdominal pain—Epirubicin—bone cancer	5.31e-05	0.000714	CcSEcCtD
Bicalutamide—Body temperature increased—Epirubicin—bone cancer	5.31e-05	0.000714	CcSEcCtD
Bicalutamide—Hypersensitivity—Methotrexate—bone cancer	5.29e-05	0.000711	CcSEcCtD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	5.23e-05	0.00725	CbGpPWpGaD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	5.16e-05	0.00716	CbGpPWpGaD
Bicalutamide—Asthenia—Methotrexate—bone cancer	5.15e-05	0.000692	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	5.15e-05	0.00713	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	5.12e-05	0.0071	CbGpPWpGaD
Bicalutamide—Feeling abnormal—Doxorubicin—bone cancer	5.12e-05	0.000689	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Doxorubicin—bone cancer	5.08e-05	0.000683	CcSEcCtD
Bicalutamide—Pruritus—Methotrexate—bone cancer	5.08e-05	0.000683	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	5.01e-05	0.00694	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.96e-05	0.00688	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Epirubicin—bone cancer	4.95e-05	0.000665	CcSEcCtD
Bicalutamide—Urticaria—Doxorubicin—bone cancer	4.94e-05	0.000664	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—RB1—bone cancer	4.93e-05	0.00683	CbGpPWpGaD
Bicalutamide—Abdominal pain—Doxorubicin—bone cancer	4.91e-05	0.000661	CcSEcCtD
Bicalutamide—Body temperature increased—Doxorubicin—bone cancer	4.91e-05	0.000661	CcSEcCtD
Bicalutamide—Diarrhoea—Methotrexate—bone cancer	4.91e-05	0.00066	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.9e-05	0.00678	CbGpPWpGaD
Bicalutamide—Asthenia—Epirubicin—bone cancer	4.82e-05	0.000648	CcSEcCtD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	4.81e-05	0.00667	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	4.77e-05	0.00661	CbGpPWpGaD
Bicalutamide—Pruritus—Epirubicin—bone cancer	4.75e-05	0.000639	CcSEcCtD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	4.75e-05	0.00658	CbGpPWpGaD
Bicalutamide—Dizziness—Methotrexate—bone cancer	4.75e-05	0.000638	CcSEcCtD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	4.71e-05	0.00652	CbGpPWpGaD
Bicalutamide—Diarrhoea—Epirubicin—bone cancer	4.6e-05	0.000618	CcSEcCtD
Bicalutamide—Hypersensitivity—Doxorubicin—bone cancer	4.58e-05	0.000616	CcSEcCtD
Bicalutamide—Vomiting—Methotrexate—bone cancer	4.56e-05	0.000614	CcSEcCtD
Bicalutamide—Rash—Methotrexate—bone cancer	4.53e-05	0.000608	CcSEcCtD
Bicalutamide—Dermatitis—Methotrexate—bone cancer	4.52e-05	0.000608	CcSEcCtD
Bicalutamide—Headache—Methotrexate—bone cancer	4.5e-05	0.000605	CcSEcCtD
Bicalutamide—Asthenia—Doxorubicin—bone cancer	4.46e-05	0.0006	CcSEcCtD
Bicalutamide—Dizziness—Epirubicin—bone cancer	4.44e-05	0.000597	CcSEcCtD
Bicalutamide—Pruritus—Doxorubicin—bone cancer	4.4e-05	0.000591	CcSEcCtD
Bicalutamide—Vomiting—Epirubicin—bone cancer	4.27e-05	0.000574	CcSEcCtD
Bicalutamide—Nausea—Methotrexate—bone cancer	4.26e-05	0.000573	CcSEcCtD
Bicalutamide—Diarrhoea—Doxorubicin—bone cancer	4.25e-05	0.000572	CcSEcCtD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.24e-05	0.00588	CbGpPWpGaD
Bicalutamide—Rash—Epirubicin—bone cancer	4.23e-05	0.000569	CcSEcCtD
Bicalutamide—Dermatitis—Epirubicin—bone cancer	4.23e-05	0.000569	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—NR1I2—bone cancer	4.22e-05	0.00585	CbGpPWpGaD
Bicalutamide—Headache—Epirubicin—bone cancer	4.21e-05	0.000566	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—MDM2—bone cancer	4.2e-05	0.00582	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.15e-05	0.00575	CbGpPWpGaD
Bicalutamide—Dizziness—Doxorubicin—bone cancer	4.11e-05	0.000553	CcSEcCtD
Bicalutamide—Nausea—Epirubicin—bone cancer	3.99e-05	0.000536	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	3.98e-05	0.00551	CbGpPWpGaD
Bicalutamide—Vomiting—Doxorubicin—bone cancer	3.95e-05	0.000531	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	3.94e-05	0.00546	CbGpPWpGaD
Bicalutamide—Rash—Doxorubicin—bone cancer	3.92e-05	0.000527	CcSEcCtD
Bicalutamide—Dermatitis—Doxorubicin—bone cancer	3.91e-05	0.000526	CcSEcCtD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	3.9e-05	0.00541	CbGpPWpGaD
Bicalutamide—Headache—Doxorubicin—bone cancer	3.89e-05	0.000523	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	3.87e-05	0.00536	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	3.87e-05	0.00536	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CDK4—bone cancer	3.71e-05	0.00514	CbGpPWpGaD
Bicalutamide—Nausea—Doxorubicin—bone cancer	3.69e-05	0.000496	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—JUN—bone cancer	3.65e-05	0.00506	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BRAF—bone cancer	3.29e-05	0.00455	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—RB1—bone cancer	3.23e-05	0.00447	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.08e-05	0.00426	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—FUS—bone cancer	2.93e-05	0.00406	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—EGFR—bone cancer	2.87e-05	0.00398	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MDM2—bone cancer	2.75e-05	0.00381	CbGpPWpGaD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	2.68e-05	0.00372	CbGpPWpGaD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	2.45e-05	0.00339	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—JUN—bone cancer	2.39e-05	0.00332	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—JUN—bone cancer	2.33e-05	0.00323	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.28e-05	0.00316	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	2.25e-05	0.00312	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	2.22e-05	0.00308	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.2e-05	0.00305	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP3A4—bone cancer	2.07e-05	0.00287	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	2.05e-05	0.00285	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	2.04e-05	0.00283	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NR1I2—bone cancer	2.03e-05	0.00281	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	2.03e-05	0.00281	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.98e-05	0.00275	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—GSTP1—bone cancer	1.93e-05	0.00267	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	1.9e-05	0.00263	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EGFR—bone cancer	1.88e-05	0.00261	CbGpPWpGaD
Bicalutamide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	1.79e-05	0.00248	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—GSTP1—bone cancer	1.77e-05	0.00246	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—GSTP1—bone cancer	1.76e-05	0.00243	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	1.75e-05	0.00242	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	1.73e-05	0.0024	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—bone cancer	1.58e-05	0.00219	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.56e-05	0.00216	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—EIF2S1—bone cancer	1.5e-05	0.00208	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NDUFA12—bone cancer	1.35e-05	0.00187	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.31e-05	0.00181	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—EZH2—bone cancer	1.3e-05	0.00181	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NDUFA12—bone cancer	1.24e-05	0.00172	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NDUFA12—bone cancer	1.23e-05	0.00171	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.16e-05	0.00161	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.14e-05	0.00158	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NT5C3A—bone cancer	1.12e-05	0.00155	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NT5C3A—bone cancer	1.03e-05	0.00143	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NT5C3A—bone cancer	1.02e-05	0.00141	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NDUFA12—bone cancer	8.12e-06	0.00113	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NT5C3A—bone cancer	6.73e-06	0.000933	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ENO2—bone cancer	4.9e-06	0.000679	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—DHFR—bone cancer	4.55e-06	0.00063	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ENO2—bone cancer	4.51e-06	0.000625	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ENO2—bone cancer	4.47e-06	0.000619	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GNA11—bone cancer	4.25e-06	0.000589	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—DHFR—bone cancer	4.18e-06	0.00058	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—DHFR—bone cancer	4.15e-06	0.000575	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GNA11—bone cancer	3.91e-06	0.000542	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GNA11—bone cancer	3.88e-06	0.000537	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP3A4—bone cancer	3.85e-06	0.000534	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.83e-06	0.000531	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP3A4—bone cancer	3.54e-06	0.000491	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP3A4—bone cancer	3.51e-06	0.000487	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.5e-06	0.000484	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTP1—bone cancer	3.3e-06	0.000457	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTP1—bone cancer	3.03e-06	0.00042	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTP1—bone cancer	3.01e-06	0.000416	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ENO2—bone cancer	2.95e-06	0.000408	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—DHFR—bone cancer	2.74e-06	0.000379	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GNA11—bone cancer	2.56e-06	0.000354	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTP1—bone cancer	1.98e-06	0.000275	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTGS2—bone cancer	1.71e-06	0.000237	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTGS2—bone cancer	1.57e-06	0.000218	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTGS2—bone cancer	1.56e-06	0.000216	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTGS2—bone cancer	1.03e-06	0.000142	CbGpPWpGaD
